Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 07/29 03:25:42 pm
312.05 USD   -0.45%
02:32pPFIZER : Israel to offer 3rd COVID booster shot to older citizens
AQ
06:15aEUROPEAN MIDDAY BRIEFING : Stocks Rise as -2-
DJ
12:22aEMEA MORNING BRIEFING : Stocks to Open Lower After -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release: Pfizer and BioNTech Receive First -3-

05/28/2021 | 03:45pm EDT
demand for any products may be reduced or no longer exist; the ability 
of BioNTech to supply the quantities of BNT162 to support clinical 
development and market demand, including our production estimates for 
2021; and challenges related to public vaccine confidence or awareness. 
Any forward-looking statements in this press release are based on 
BioNTech's current expectations and beliefs of future events, and are 
subject to a number of risks and uncertainties that could cause actual 
results to differ materially and adversely from those set forth in or 
implied by such forward-looking statements. These risks and 
uncertainties include, but are not limited to: the ability to meet the 
pre-defined endpoints in clinical trials; competition to create a 
vaccine for COVID-19; the ability to produce comparable clinical or 
other results, including our stated rate of vaccine effectiveness and 
safety and tolerability profile observed to date, in the remainder of 
the trial or in larger, more diverse populations upon commercialization; 
the ability to effectively scale our productions capabilities; and other 
potential difficulties. 
 
   For a discussion of these and other risks and uncertainties, see 
BioNTech's Annual Report on Form 20-F for the Year Ended December 31, 
2020, filed with the SEC on March 30, 2021, which is available on the 
SEC's website at www.sec.gov. All information in this press release is 
as of the date of the release, and BioNTech undertakes no duty to update 
this information unless required by law. 
 
   Pfizer Contacts: 
 
   Media Relations 
 
   Andrew Widger 
 
   +44 1737 330909 
 
   https://www.globenewswire.com/Tracker?data=xlItrdL-PFwIHp8k4EN8T_vLP2gXhMqQSjYaTF-E-P04MAj6srUMc0CEVNNEEEAb6hstz60My6zy7gTJJK3XYk8gjcsREnqAsAwTXkdrvFsaFFVIsQA_m8zEbdjs7i5r 
Andrew.Widger@Pfizer.com 
 
   Investor Relations 
 
   Chuck Triano 
 
   +1 (212) 733-3901 
 
   https://www.globenewswire.com/Tracker?data=Pgd6oDeq0fwPw8CNvbIwUgSL1sGypoQH8yaAcn5nZzmR6BzDJ5Yvlxxgb9nc4-_z6iI_RB-5O2PKmktRQKo3mi_LfrrNhfMupyAt-S1PY20Qw3FputbcEdXkK5C8hEHw 
Charles.E.Triano@Pfizer.com 
 
   BioNTech Contacts: 
 
   Media Relations 
 
   Jasmina Alatovic 
 
   +49 (0)6131 9084 1513 
 
   https://www.globenewswire.com/Tracker?data=a_CM2QghIvxzoXTBidUUPNaZ19DVkoFcz5gMsWS4m5X3QmUSIUFOZHgPFJWst9VRrqBSHthSZ2BEHrN2NMd29ZXfOFp_n9P1qIPcoE3u4gc= 
Media@biontech.de 
 
   Investor Relations 
 
   Sylke Maas, Ph.D. 
 
   +49 (0)6131 9084 1074 
 
   https://www.globenewswire.com/Tracker?data=FgZDfHl6-dyLVkqcZnxZFaORbM3rDiNLcjMlQpOEEaDmAckWM0vTeqUPSuQsV_k5UIEUyRXx6YWUGgv6ojfM9xIIxQuQcIuzBN8JbvhllHw= 
Investors@biontech.de 
 
 
 
 

(END) Dow Jones Newswires

May 28, 2021 15:45 ET (19:45 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -0.08% 312.89 Delayed Quote.284.51%
DJ INDUSTRIAL 0.52% 35112.8 Delayed Quote.14.55%
PFIZER, INC. -0.70% 42.77 Delayed Quote.18.04%
All news about BIONTECH SE
02:32pPFIZER : Israel to offer 3rd COVID booster shot to older citizens
AQ
06:15aEUROPEAN MIDDAY BRIEFING : Stocks Rise as -2-
DJ
12:22aEMEA MORNING BRIEFING : Stocks to Open Lower After -2-
DJ
07/28MODERNA : Pfizer says 2021 COVID-19 vaccine sales to top $33.5 billion, sees nee..
RE
07/28STREET COLOR : Efficacy of Pfizer/BioNTech COVID-19 Vaccine Falls to 84% From 96..
MT
07/28GLOBAL MARKETS LIVE : Apple, Alphabet, Facebook, Pfizer, McDonald's...
07/28PFIZER : Reports Higher Second-Quarter Results as COVID-19 Vaccine Gives Boost, ..
MT
07/28Today on Wall Street: Better-than-expected earnings ahead of the Fed
07/28PFIZER : hikes Covid vaccine sales forecast by almost a third to $33.5bn
AQ
07/28PFIZER : Lifts 2021 Guidance For COVID-19 Vaccine Sales
MT
More news
Financials
Sales 2021 12 451 M 14 801 M 14 801 M
Net income 2021 7 102 M 8 442 M 8 442 M
Net cash 2021 7 718 M 9 175 M 9 175 M
P/E ratio 2021 9,30x
Yield 2021 -
Capitalization 63 907 M 75 705 M 75 967 M
EV / Sales 2021 4,51x
EV / Sales 2022 4,72x
Nbr of Employees 2 200
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 264,60 €
Average target price 155,21 €
Spread / Average Target -41,3%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Sierk P÷tting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE284.51%75 705
GILEAD SCIENCES, INC.20.25%87 868
WUXI APPTEC CO., LTD.38.94%68 994
REGENERON PHARMACEUTICALS21.38%60 726
VERTEX PHARMACEUTICALS-14.43%52 353
GENMAB A/S13.76%29 077